Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 336

1.

The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy.

Black AJ, Zargar H, Zargar-Shoshtari K, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Griffin J, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Spiess PE, Daneshmand S, Sridhar SS, Black PC.

Urol Oncol. 2019 Oct 29. pii: S1078-1439(19)30374-6. doi: 10.1016/j.urolonc.2019.09.023. [Epub ahead of print]

PMID:
31676278
2.

African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study (PASS).

Schenk JM, Newcomb LF, Zheng Y, Faino AV, Zhu K, Nyame YA, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW.

J Urol. 2019 Oct 25:101097JU0000000000000621. doi: 10.1097/JU.0000000000000621. [Epub ahead of print]

PMID:
31651227
3.

Tissue-based genomics: which test and when.

Vince RA Jr, Tosoian JJ, Jackson WC, Spratt DE, Morgan TM.

Curr Opin Urol. 2019 Nov;29(6):598-604. doi: 10.1097/MOU.0000000000000673.

PMID:
31584886
4.

Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer.

Spratt DE, Alshalalfa M, Fishbane N, Weiner AB, Mehra R, Mahal BA, Lehrer J, Liu Y, Zhao SG, Speers C, Morgan TM, Dicker AP, Freedland SJ, Karnes RJ, Weinmann S, Davicioni E, Ross AE, Den RB, Nguyen PL, Feng FY, Lotan TL, Chinnaiyan AM, Schaeffer EM.

Clin Cancer Res. 2019 Sep 12. doi: 10.1158/1078-0432.CCR-19-1587. [Epub ahead of print]

PMID:
31515456
5.

Human papillomavirus E7 oncoprotein targets RNF168 to hijack the host DNA damage response.

Sitz J, Blanchet SA, Gameiro SF, Biquand E, Morgan TM, Galloy M, Dessapt J, Lavoie EG, Blondeau A, Smith BC, Mymryk JS, Moody CA, Fradet-Turcotte A.

Proc Natl Acad Sci U S A. 2019 Sep 24;116(39):19552-19562. doi: 10.1073/pnas.1906102116. Epub 2019 Sep 9.

PMID:
31501315
6.

Clinical outcomes in men with prostate cancer who selected active surveillance using a clinical cell cycle risk score.

Kaul S, Wojno KJ, Stone S, Evans B, Bernhisel R, Meek S, D'Anna RE, Ferguson J, Glaser J, Morgan TM, Lieb J, Yan R, Cohen T, Ehdaie B.

Per Med. 2019 Nov;16(6):491-499. doi: 10.2217/pme-2019-0084. Epub 2019 Sep 4.

7.

Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts.

Drost FH, Nieboer D, Morgan TM, Carroll PR, Roobol MJ; Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP) Consortium.

Eur Urol. 2019 Nov;76(5):693-702. doi: 10.1016/j.eururo.2019.07.041. Epub 2019 Aug 24.

PMID:
31451332
8.

Detection and isolation of disseminated tumor cells in bone marrow of patients with clinically localized prostate cancer.

Cackowski FC, Wang Y, Decker JT, Sifuentes C, Weindorf S, Jung Y, Wang Y, Decker AM, Yumoto K, Szerlip N, Buttitta L, Pienta KJ, Morgan TM, Taichman RS.

Prostate. 2019 Oct;79(14):1715-1727. doi: 10.1002/pros.23896. Epub 2019 Aug 26.

PMID:
31449673
9.

High-dose-rate prostate brachytherapy appears safe in patients with high baseline International Prostate Symptom Scores.

Morgan TM, Rossi PJ, Cutrell PK, Zhang C, Press RH, Rahnema S, Sanda M, Pattaras J, Cimmino C, Hershatter B, Jani AB, Patel PR.

Brachytherapy. 2019 Jul 20. pii: S1538-4721(19)30108-4. doi: 10.1016/j.brachy.2019.06.001. [Epub ahead of print]

PMID:
31337543
10.

Clinical and morphologic review of 60 hereditary renal tumors from 30 hereditary renal cell carcinoma syndrome patients: lessons from a contemporary single institution series.

Kennedy JM, Wang X, Plouffe KR, Dhanasekaran SM, Hafez K, Palapattu GS, Else T, Weizer AZ, Morgan TM, Spratt DE, Davenport MS, Chinnaiyan AM, Udager AM, Mehra R.

Med Oncol. 2019 Jul 22;36(9):74. doi: 10.1007/s12032-019-1297-6.

PMID:
31332543
11.

Circulating Tumor Cell-Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer.

Chung JS, Wang Y, Henderson J, Singhal U, Qiao Y, Zaslavsky AB, Hovelson DH, Spratt DE, Reichert Z, Palapattu GS, Taichman RS, Tomlins SA, Morgan TM.

Neoplasia. 2019 Aug;21(8):802-809. doi: 10.1016/j.neo.2019.06.002. Epub 2019 Jul 2.

12.

Overdiagnosis and lives saved due to reflex testing men with intermediate prostate-specific antigen levels.

Gulati R, Morgan TM, A'mar T, Psutka SP, Tosoian JJ, Etzioni R.

J Natl Cancer Inst. 2019 Jun 21. pii: djz127. doi: 10.1093/jnci/djz127. [Epub ahead of print]

PMID:
31225597
13.

The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement.

Cooperberg MR, Carroll PR, Dall'Era MA, Davies BJ, Davis JW, Eggener SE, Feng FY, Lin DW, Morgan TM, Morgans AK, Spratt DE, Taneja SS, Penson DF.

Eur Urol. 2019 Sep;76(3):268-272. doi: 10.1016/j.eururo.2019.05.013. Epub 2019 May 23.

PMID:
31128968
14.

Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality.

Dess RT, Hartman HE, Mahal BA, Soni PD, Jackson WC, Cooperberg MR, Amling CL, Aronson WJ, Kane CJ, Terris MK, Zumsteg ZS, Butler S, Osborne JR, Morgan TM, Mehra R, Salami SS, Kishan AU, Wang C, Schaeffer EM, Roach M 3rd, Pisansky TM, Shipley WU, Freedland SJ, Sandler HM, Halabi S, Feng FY, Dignam JJ, Nguyen PL, Schipper MJ, Spratt DE.

JAMA Oncol. 2019 Jul 1;5(7):975-983. doi: 10.1001/jamaoncol.2019.0826.

15.

Staging the Host: Personalizing Risk Assessment for Radical Cystectomy Patients.

Psutka SP, Barocas DA, Catto JWF, Gore JL, Lee CT, Morgan TM, Master VA, Necchi A, Rouprêt M, Boorjian SA.

Eur Urol Oncol. 2018 Sep;1(4):292-304. doi: 10.1016/j.euo.2018.05.010. Epub 2018 Jun 19. Review.

PMID:
31100250
16.

Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer-specific Mortality: Competition Between Age and Time to Biochemical Failure.

Jackson WC, Suresh K, Tumati V, Dess RT, Soni PD, Zhao SG, Zumsteg ZS, Hannan R, Hollenbeck BK, George A, Kaffenberger SD, Salami SS, Hearn JWD, Morgan TM, Mehra R, Schipper M, Feng FY, Desai NB, Spratt DE.

Eur Urol Oncol. 2018 Sep;1(4):276-282. doi: 10.1016/j.euo.2018.04.014. Epub 2018 Sep 28.

PMID:
31100248
17.

Liquid biopsy: Where did it come from, what is it, and where is it going?

Morgan TM.

Investig Clin Urol. 2019 May;60(3):139-141. doi: 10.4111/icu.2019.60.3.139. Epub 2019 Apr 29. No abstract available.

18.

Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies.

Jackson WC, Silva J, Hartman HE, Dess RT, Kishan AU, Beeler WH, Gharzai LA, Jaworski EM, Mehra R, Hearn JWD, Morgan TM, Salami SS, Cooperberg MR, Mahal BA, Soni PD, Kaffenberger S, Nguyen PL, Desai N, Feng FY, Zumsteg ZS, Spratt DE.

Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):778-789. doi: 10.1016/j.ijrobp.2019.03.051. Epub 2019 Apr 6.

PMID:
30959121
19.

EDITORIAL COMMENT.

Singhal U, Morgan TM, Tosoian JJ.

Urology. 2019 Apr;126:82. doi: 10.1016/j.urology.2018.11.051. No abstract available.

PMID:
30929696
20.

Bringing Prostate Cancer Germline Genetics into Clinical Practice.

Das S, Salami SS, Spratt DE, Kaffenberger SD, Jacobs MF, Morgan TM.

J Urol. 2019 Aug;202(2):223-230. doi: 10.1097/JU.0000000000000137. Epub 2019 Jul 8. Review.

PMID:
30730411
21.

Individual and Population Comparisons of Surgery and Radiotherapy Outcomes in Prostate Cancer Using Bayesian Multistate Models.

Beesley LJ, Morgan TM, Spratt DE, Singhal U, Feng FY, Furgal AC, Jackson WC, Daignault S, Taylor JMG.

JAMA Netw Open. 2019 Feb 1;2(2):e187765. doi: 10.1001/jamanetworkopen.2018.7765.

22.

Utilization of Salvage Radiation Therapy for Biochemical Recurrence After Radical Prostatectomy.

Hawken SR, Spratt DE, Qi J, Linsell SM, Cher ML, Ghani KR, Miller DC, Montie JE, Morgan TM; Michigan Urological Surgery Improvement Collaborative.

Int J Radiat Oncol Biol Phys. 2019 Aug 1;104(5):1030-1034. doi: 10.1016/j.ijrobp.2019.01.006. Epub 2019 Jan 23.

PMID:
30682490
23.

Pathogenic variants in USP7 cause a neurodevelopmental disorder with speech delays, altered behavior, and neurologic anomalies.

Fountain MD, Oleson DS, Rech ME, Segebrecht L, Hunter JV, McCarthy JM, Lupo PJ, Holtgrewe M, Moran R, Rosenfeld JA, Isidor B, Le Caignec C, Saenz MS, Pedersen RC, Morgan TM, Pfotenhauer JP, Xia F, Bi W, Kang SL, Patel A, Krantz ID, Raible SE, Smith W, Cristian I, Torti E, Juusola J, Millan F, Wentzensen IM, Person RE, Küry S, Bézieau S, Uguen K, Férec C, Munnich A, van Haelst M, Lichtenbelt KD, van Gassen K, Hagelstrom T, Chawla A, Perry DL, Taft RJ, Jones M, Masser-Frye D, Dyment D, Venkateswaran S, Li C, Escobar LF, Horn D, Spillmann RC, Peña L, Wierzba J, Strom TM, Parenti I, Kaiser FJ, Ehmke N, Schaaf CP.

Genet Med. 2019 Aug;21(8):1797-1807. doi: 10.1038/s41436-019-0433-1. Epub 2019 Jan 25.

24.

Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS).

Newcomb LF, Zheng Y, Faino AV, Bianchi-Frias D, Cooperberg MR, Brown MD, Brooks JD, Dash A, Fabrizio MD, Gleave ME, Liss M, Morgan TM, Thompson IM, Wagner AA, Carroll PR, Nelson PS, Lin DW.

Prostate Cancer Prostatic Dis. 2019 Sep;22(3):438-445. doi: 10.1038/s41391-018-0124-z. Epub 2019 Jan 21.

25.

Brachytherapy for localized prostate cancer in the modern era: a comparison of patient-reported quality of life outcomes among different techniques.

Morgan TM, Press RH, Cutrell PK, Zhang C, Chen Z, Rahnema S, Sanda M, Pattaras J, Patel PR, Jani AB, Rossi PJ.

J Contemp Brachytherapy. 2018 Dec;10(6):495-502. doi: 10.5114/jcb.2018.81024. Epub 2018 Dec 28.

26.

Optimizing Prostate Cancer Surveillance: Using Data-driven Models for Informed Decision-making.

Denton BT, Hawley ST, Morgan TM.

Eur Urol. 2019 Jun;75(6):918-919. doi: 10.1016/j.eururo.2018.12.006. Epub 2018 Dec 19. No abstract available.

PMID:
30578121
27.

Clinical utility and concordance of upper urinary tract cytology and biopsy in predicting clinicopathological features of upper urinary tract urothelial carcinoma.

Simon CT, Skala SL, Weizer AZ, Ambani SN, Chinnaiyan AM, Palapattu G, Hafez K, Magers MJ, Kaffenberger SD, Spratt DE, Montgomery JS, Morgan TM, Udager AM, Lew M, Mehra R.

Hum Pathol. 2019 Apr;86:76-84. doi: 10.1016/j.humpath.2018.11.021. Epub 2018 Dec 8.

PMID:
30537495
28.

Asymptomatic myocardial ischemia forecasts adverse events in cardiovascular magnetic resonance dobutamine stress testing of high-risk middle-aged and elderly individuals.

Stacey RB, Vera T, Morgan TM, Jordan JH, Whitlock MC, Hall ME, Vasu S, Hamilton C, Kitzman DW, Hundley WG.

J Cardiovasc Magn Reson. 2018 Nov 22;20(1):75. doi: 10.1186/s12968-018-0492-5.

29.

Transcriptomic heterogeneity in multifocal prostate cancer.

Salami SS, Hovelson DH, Kaplan JB, Mathieu R, Udager AM, Curci NE, Lee M, Plouffe KR, de la Vega LL, Susani M, Rioux-Leclercq N, Spratt DE, Morgan TM, Davenport MS, Chinnaiyan AM, Cyrta J, Rubin MA, Shariat SF, Tomlins SA, Palapattu GS.

JCI Insight. 2018 Nov 2;3(21). pii: 123468. doi: 10.1172/jci.insight.123468.

30.

Fractionated Radiotherapy Is Associated with Lower Rates of Treatment-Related Edema than Stereotactic Radiosurgery in Magnetic Resonance Imaging-Defined Meningiomas.

Morgan TM, Zaenger D, Switchenko JM, Eaton BR, Crocker IR, Ali AN, Shu HG.

World Neurosurg. 2019 Jan;121:e640-e646. doi: 10.1016/j.wneu.2018.09.179. Epub 2018 Oct 4.

31.

Patient-reported health-related quality of life outcomes after HDR brachytherapy between small (<60 cc) and large (≥60 cc) prostate glands.

Press RH, Morgan TM, Cutrell PK, Zhang C, Chen Z, Rahnema S, Sanda M, Pattaras J, Patel P, Jani AB, Rossi PJ.

Brachytherapy. 2019 Jan - Feb;18(1):13-21. doi: 10.1016/j.brachy.2018.08.009. Epub 2018 Sep 25.

PMID:
30262410
32.

Pathological upgrading at radical prostatectomy for patients with Grade Group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance.

Kaye DR, Qi J, Morgan TM, Linsell S, Ginsburg KB, Lane BR, Montie JE, Cher ML, Miller DC; Michigan Urological Surgery Improvement Collaborative.

BJU Int. 2019 May;123(5):846-853. doi: 10.1111/bju.14554. Epub 2018 Oct 15.

PMID:
30248225
33.

Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline.

Bekelman JE, Rumble RB, Chen RC, Pisansky TM, Finelli A, Feifer A, Nguyen PL, Loblaw DA, Tagawa ST, Gillessen S, Morgan TM, Liu G, Vapiwala N, Haluschak JJ, Stephenson A, Touijer K, Kungel T, Freedland SJ.

J Clin Oncol. 2018 Sep 5:JCO1800606. doi: 10.1200/JCO.18.00606. [Epub ahead of print]

PMID:
30183466
34.

International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone Therapy.

Berlin A, Moraes FY, Sanmamed N, Glicksman R, Koven A, Espin-Garcia O, Leite ETT, Silva JLF, Gadia R, Nesbitt M, Catton CN, Kaffenberger S, Salami SS, Morgan TM, Hearn JWD, Jackson WC, Mehra R, Chung P, Fleshner NE, Zumsteg ZS, Dess RT, Feng FY, Finelli A, Spratt DE.

J Urol. 2019 Feb;201(2):284-291. doi: 10.1016/j.juro.2018.08.044.

PMID:
30153435
35.

Genomic Screening: The Mutation and the Mustard Seed.

Morgan TM.

J Law Med Ethics. 2018 Jun;46(2):541-546. doi: 10.1177/1073110518782963. No abstract available.

PMID:
30146977
36.

Measurement of circulating tumor cells in squamous cell carcinoma of the head and neck and patient outcomes.

Morgan TM, Wang X, Qian X, Switchenko JM, Nie S, Patel KR, Cassidy RJ, Shin DM, Beitler JJ.

Clin Transl Oncol. 2019 Mar;21(3):342-347. doi: 10.1007/s12094-018-1930-4. Epub 2018 Aug 6.

37.

Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS.

Kearns JT, Faino AV, Schenk JM, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner A, Zheng Y, Lin DW.

J Urol. 2019 Jan;201(1):106-111. doi: 10.1016/j.juro.2018.07.065.

PMID:
30076904
38.

Hypofractionated external beam radiation therapy in combination with HDR boost for localized prostate cancer: patient reported quality of life outcomes.

Morgan TM, Press RH, Cutrell PK, Zhang C, Chen Z, Rahnema S, Jhaveri J, Sanda M, Pattaras J, Patel P, Jani AB, Rossi PJ.

J Contemp Brachytherapy. 2018 Jun;10(3):211-217. doi: 10.5114/jcb.2018.76980. Epub 2018 Jun 30.

39.

Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.

Hovelson DH, Udager AM, McDaniel AS, Grivas P, Palmbos P, Tamura S, Lazo de la Vega L, Palapattu G, Veeneman B, El-Sawy L, Sadis SE, Morgan TM, Montgomery JS, Weizer AZ, Day KC, Neamati N, Liebert M, Keller ET, Day ML, Mehra R, Tomlins SA.

Eur Urol. 2018 Dec;74(6):741-753. doi: 10.1016/j.eururo.2018.06.047. Epub 2018 Jul 20.

PMID:
30033047
40.

Tradeoffs in Refining the Diagnosis of Prostate Cancer.

Modi PK, Morgan TM.

Eur Urol. 2018 Dec;74(6):729-730. doi: 10.1016/j.eururo.2018.07.008. Epub 2018 Jul 19. No abstract available.

PMID:
30031570
41.

The effect of Aliskiren on exercise capacity in older patients with heart failure and preserved ejection fraction: A randomized, placebo-controlled, double-blind trial.

Upadhya B, Brubaker PH, Morgan TM, Eggebeen JD, Jao GT, Stewart KP, Kitzman DW.

Am Heart J. 2018 Jul;201:164-167. doi: 10.1016/j.ahj.2018.03.019. Epub 2018 Apr 4.

PMID:
29910050
42.

Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy.

Vasdev N, Zargar H, Noël JP, Veeratterapillay R, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Morgan TM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Holzbeierlein JM, Thorpe A, Black PC.

World J Urol. 2019 Jan;37(1):165-172. doi: 10.1007/s00345-018-2361-0. Epub 2018 Jun 7.

PMID:
29882105
43.

Association Between Early Confirmatory Testing and the Adoption of Active Surveillance for Men With Favorable-risk Prostate Cancer.

Kaye DR, Qi J, Morgan TM, Linsell S, Lane BR, Montie JE, Cher ML, Miller DC; Michigan Urological Surgery Improvement Collaborative.

Urology. 2018 Aug;118:127-133. doi: 10.1016/j.urology.2018.04.038. Epub 2018 May 21.

PMID:
29792972
44.

Multi-institutional Survival Analysis of Incidental Pathologic T3a Upstaging in Clinical T1 Renal Cell Carcinoma Following Partial Nephrectomy.

Russell CM, Lebastchi AH, Chipollini J, Niemann A, Mehra R, Morgan TM, Miller DC, Palapattu GS, Hafez KS, Sexton WJ, Spiess PE, Weizer AZ.

Urology. 2018 Jul;117:95-100. doi: 10.1016/j.urology.2018.04.002. Epub 2018 Apr 17.

PMID:
29678662
45.

Does size matter? Investigating the optimal planning target volume margin for postoperative stereotactic radiosurgery to resected brain metastases.

Jhaveri J, Chowdhary M, Zhang X, Press RH, Switchenko JM, Ferris MJ, Morgan TM, Roper J, Dhabaan A, Elder E, Eaton BR, Olson JJ, Curran WJ, Shu HG, Crocker IR, Patel KR.

J Neurosurg. 2018 Apr 20;130(3):797-803. doi: 10.3171/2017.9.JNS171735.

46.

Prognostic importance of lymphovascular invasion in urothelial carcinoma of the renal pelvis.

Danzig MR, Mallin K, McKiernan JM, Stadler WM, Sridhar SS, Morgan TM, Bochner BH, Lee CT.

Cancer. 2018 Jun 15;124(12):2507-2514. doi: 10.1002/cncr.31372. Epub 2018 Apr 6.

47.

Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature.

Singhal U, Wang Y, Henderson J, Niknafs YS, Qiao Y, Gursky A, Zaslavsky A, Chung JS, Smith DC, Karnes RJ, Chang SL, Feng FY, Palapattu GS, Taichman RS, Chinnaiyan AM, Tomlins SA, Morgan TM.

Mol Cancer Res. 2018 Apr;16(4):643-654. doi: 10.1158/1541-7786.MCR-17-0539. Epub 2018 Feb 16.

48.

Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.

Cooperberg MR, Brooks JD, Faino AV, Newcomb LF, Kearns JT, Carroll PR, Dash A, Etzioni R, Fabrizio MD, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW, Zheng Y.

Eur Urol. 2018 Aug;74(2):211-217. doi: 10.1016/j.eururo.2018.01.017. Epub 2018 Feb 9.

49.

Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study.

Kearns JT, Faino AV, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Zheng Y, Lin DW.

Eur Urol. 2018 May;73(5):706-712. doi: 10.1016/j.eururo.2018.01.016. Epub 2018 Feb 9.

50.

CXCL12γ Promotes Metastatic Castration-Resistant Prostate Cancer by Inducing Cancer Stem Cell and Neuroendocrine Phenotypes.

Jung Y, Cackowski FC, Yumoto K, Decker AM, Wang J, Kim JK, Lee E, Wang Y, Chung JS, Gursky AM, Krebsbach PH, Pienta KJ, Morgan TM, Taichman RS.

Cancer Res. 2018 Apr 15;78(8):2026-2039. doi: 10.1158/0008-5472.CAN-17-2332. Epub 2018 Feb 5.

Supplemental Content

Loading ...
Support Center